Global Biologics and Biosimilars Market Size By Segmentations, Top Key Players, Trend, Future Development & Forecast 2024-2035
- PUBLISHED ON
- 11/23/2022
- NO OF PAGES
- 252
- CATEGORY
- Healthcare & Life Sciences
The competitive landscape analysis of Biologics and Biosimilars Market uncovers detailed company profiles, revenue shares, portfolio innovations, regional product footprint, key developmental strategies, pricing structure, target markets, and near-term plans of market leaders. This entire section helps readers gain an essence of what is driving competition and what would help them stand out to win new target markets.
Market estimates and forecast are backed by an extensive primary research, further complemented by on-point secondary research of Biologics and Biosimilars Market. The research analysts have invested significant time and effort in gathering critical industry information from KIPs such as OEMs, top suppliers and distributors, and government bodies.
Market Segmentations:
The research report includes specific segments by region (country), by Company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Global Biologics and Biosimilars Market: By Types
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others
Global Biologics and Biosimilars Market: By Applications
Tumor
Diabetes
Cardiovascular
Hemophilia
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Global Biologics and Biosimilars Market: Top Key Players
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Global Biologics and Biosimilars Market: Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent sub-markets of various marketspaces. The key players in the markets are identified through secondary research, and their market contributions in different applications across regions and globally were determined through primary and secondary research. This entire process included the study of the annual and financial reports of the top market players and extensive interviews for key insights with industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All the possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to arrive at the final quantitative and qualitative data. This data has been consolidated, and detailed inputs and analysis from Analytics Market Research added before being presented in this report.
Reasons to Purchase Biologics and Biosimilars Market Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
Frequently Asked Questions
• What is the market size and growth projections?
• What is the market size and growth projection for each of the market segments and sub-segments across Countries & Regions?
• What are the top performing segments, and countries / regions of each of the markets?
• What is the market size and growth rate across key countries / regions?
• How big is the global & regional market in terms of revenue and volume?
• How far market will grow in forecast period in terms of revenue and volume?
• What factors will influence demand and supply trends across each markets during the forecast period?
• What are the technology trends shaping various markets?
• Which country / region has more opportunities?
• What is the COVID-19 impact on the market and how long will it take to recover?
• Who are the key competitors of market Players?
• What are the market share (%) of Key Players?
• What are the Merger & Acquisition, New Product Launch, Recent Development within each of the Markets?
• What are PEST analysis, Ecosystem Analysis, Porter's Five Forecast Analysis, Ansoff Matrix, and SWOT Analysis among other analyses for diverse markets?
Base Year: 2023Market estimates and forecast are backed by an extensive primary research, further complemented by on-point secondary research of Biologics and Biosimilars Market. The research analysts have invested significant time and effort in gathering critical industry information from KIPs such as OEMs, top suppliers and distributors, and government bodies.
Market Segmentations:
The research report includes specific segments by region (country), by Company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Global Biologics and Biosimilars Market: By Types
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others
Global Biologics and Biosimilars Market: By Applications
Tumor
Diabetes
Cardiovascular
Hemophilia
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Global Biologics and Biosimilars Market: Top Key Players
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Global Biologics and Biosimilars Market: Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent sub-markets of various marketspaces. The key players in the markets are identified through secondary research, and their market contributions in different applications across regions and globally were determined through primary and secondary research. This entire process included the study of the annual and financial reports of the top market players and extensive interviews for key insights with industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All the possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to arrive at the final quantitative and qualitative data. This data has been consolidated, and detailed inputs and analysis from Analytics Market Research added before being presented in this report.
Reasons to Purchase Biologics and Biosimilars Market Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
Frequently Asked Questions
• What is the market size and growth projections?
• What is the market size and growth projection for each of the market segments and sub-segments across Countries & Regions?
• What are the top performing segments, and countries / regions of each of the markets?
• What is the market size and growth rate across key countries / regions?
• How big is the global & regional market in terms of revenue and volume?
• How far market will grow in forecast period in terms of revenue and volume?
• What factors will influence demand and supply trends across each markets during the forecast period?
• What are the technology trends shaping various markets?
• Which country / region has more opportunities?
• What is the COVID-19 impact on the market and how long will it take to recover?
• Who are the key competitors of market Players?
• What are the market share (%) of Key Players?
• What are the Merger & Acquisition, New Product Launch, Recent Development within each of the Markets?
• What are PEST analysis, Ecosystem Analysis, Porter's Five Forecast Analysis, Ansoff Matrix, and SWOT Analysis among other analyses for diverse markets?
Historic Year: 2016-2022
Forecast: 2024-2035
1 Biologics and Biosimilars Market Overview
1.1 Product Overview and Scope of Biologics and Biosimilars
1.2 Biologics and Biosimilars Segment by Type
1.2.1 Global Biologics and Biosimilars Sales Growth Rate Comparison by Type (2022-2030)
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Others
1.3 Biologics and Biosimilars Segment by Application
1.3.1 Biologics and Biosimilars Sales Comparison by Application: (2022-2030)
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Others
1.4 Global Biologics and Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Biologics and Biosimilars Revenue 2016-2030
1.4.2 Global Biologics and Biosimilars Sales 2016-2030
1.4.3 Biologics and Biosimilars Market Size by Region: 2016 Versus 2022 Versus 2030
2 Biologics and Biosimilars Market Competition by Manufacturers
2.1 Global Biologics and Biosimilars Sales Market Share by Manufacturers (2016-2021)
2.2 Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Biologics and Biosimilars Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Biologics and Biosimilars Manufacturing Sites, Area Served, Product Type
2.5 Biologics and Biosimilars Market Competitive Situation and Trends
2.5.1 Biologics and Biosimilars Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Biologics and Biosimilars Players Market Share by Revenue
2.5.3 Global Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biologics and Biosimilars Retrospective Market Scenario by Region
3.1 Global Biologics and Biosimilars Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Biologics and Biosimilars Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Biologics and Biosimilars Market Facts & Figures by Country
3.3.1 North America Biologics and Biosimilars Sales by Country
3.3.2 North America Biologics and Biosimilars Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Biologics and Biosimilars Market Facts & Figures by Country
3.4.1 Europe Biologics and Biosimilars Sales by Country
3.4.2 Europe Biologics and Biosimilars Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Biologics and Biosimilars Market Facts & Figures by Region
3.5.1 Asia Pacific Biologics and Biosimilars Sales by Region
3.5.2 Asia Pacific Biologics and Biosimilars Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Biologics and Biosimilars Market Facts & Figures by Country
3.6.1 Latin America Biologics and Biosimilars Sales by Country
3.6.2 Latin America Biologics and Biosimilars Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Biologics and Biosimilars Market Facts & Figures by Country
3.7.1 Middle East and Africa Biologics and Biosimilars Sales by Country
3.7.2 Middle East and Africa Biologics and Biosimilars Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Biologics and Biosimilars Historic Market Analysis by Type
4.1 Global Biologics and Biosimilars Sales Market Share by Type (2016-2021)
4.2 Global Biologics and Biosimilars Revenue Market Share by Type (2016-2021)
4.3 Global Biologics and Biosimilars Price by Type (2016-2021)
5 Global Biologics and Biosimilars Historic Market Analysis by Application
5.1 Global Biologics and Biosimilars Sales Market Share by Application (2016-2021)
5.2 Global Biologics and Biosimilars Revenue Market Share by Application (2016-2021)
5.3 Global Biologics and Biosimilars Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Roche Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Amgen Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 AbbVie
6.3.1 AbbVie Corporation Information
6.3.2 AbbVie Description and Business Overview
6.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.3.4 AbbVie Product Portfolio
6.3.5 AbbVie Recent Developments/Updates
6.4 Sanofi-Aventis
6.4.1 Sanofi-Aventis Corporation Information
6.4.2 Sanofi-Aventis Description and Business Overview
6.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Sanofi-Aventis Product Portfolio
6.4.5 Sanofi-Aventis Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Corporation Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Johnson & Johnson Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Pfizer Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Novo Nordisk
6.6.1 Novo Nordisk Corporation Information
6.6.2 Novo Nordisk Description and Business Overview
6.6.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Novo Nordisk Product Portfolio
6.7.5 Novo Nordisk Recent Developments/Updates
6.8 Eli Lilly
6.8.1 Eli Lilly Corporation Information
6.8.2 Eli Lilly Description and Business Overview
6.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Eli Lilly Product Portfolio
6.8.5 Eli Lilly Recent Developments/Updates
6.9 Novartis
6.9.1 Novartis Corporation Information
6.9.2 Novartis Description and Business Overview
6.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Novartis Product Portfolio
6.9.5 Novartis Recent Developments/Updates
6.10 Merck
6.10.1 Merck Corporation Information
6.10.2 Merck Description and Business Overview
6.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Merck Product Portfolio
6.10.5 Merck Recent Developments/Updates
6.11 3sbio
6.11.1 3sbio Corporation Information
6.11.2 3sbio Biologics and Biosimilars Description and Business Overview
6.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.11.4 3sbio Product Portfolio
6.11.5 3sbio Recent Developments/Updates
6.12 Changchun High Tech
6.12.1 Changchun High Tech Corporation Information
6.12.2 Changchun High Tech Biologics and Biosimilars Description and Business Overview
6.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Changchun High Tech Product Portfolio
6.12.5 Changchun High Tech Recent Developments/Updates
6.13 CP Guojian
6.13.1 CP Guojian Corporation Information
6.13.2 CP Guojian Biologics and Biosimilars Description and Business Overview
6.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.13.4 CP Guojian Product Portfolio
6.13.5 CP Guojian Recent Developments/Updates
6.14 Biotech
6.14.1 Biotech Corporation Information
6.14.2 Biotech Biologics and Biosimilars Description and Business Overview
6.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Biotech Product Portfolio
6.14.5 Biotech Recent Developments/Updates
6.15 Gelgen
6.15.1 Gelgen Corporation Information
6.15.2 Gelgen Biologics and Biosimilars Description and Business Overview
6.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Gelgen Product Portfolio
6.15.5 Gelgen Recent Developments/Updates
6.16 Innovent
6.16.1 Innovent Corporation Information
6.16.2 Innovent Biologics and Biosimilars Description and Business Overview
6.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Innovent Product Portfolio
6.16.5 Innovent Recent Developments/Updates
6.17 Dong Bao
6.17.1 Dong Bao Corporation Information
6.17.2 Dong Bao Biologics and Biosimilars Description and Business Overview
6.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Dong Bao Product Portfolio
6.17.5 Dong Bao Recent Developments/Updates
6.18 Ganlee
6.18.1 Ganlee Corporation Information
6.18.2 Ganlee Biologics and Biosimilars Description and Business Overview
6.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.18.4 Ganlee Product Portfolio
6.18.5 Ganlee Recent Developments/Updates
7 Biologics and Biosimilars Manufacturing Cost Analysis
7.1 Biologics and Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Biologics and Biosimilars
7.4 Biologics and Biosimilars Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Biologics and Biosimilars Distributors List
8.3 Biologics and Biosimilars Customers
9 Biologics and Biosimilars Market Dynamics
9.1 Biologics and Biosimilars Industry Trends
9.2 Biologics and Biosimilars Growth Drivers
9.3 Biologics and Biosimilars Market Challenges
9.4 Biologics and Biosimilars Market Restraints
10 Global Market Forecast
10.1 Biologics and Biosimilars Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Biologics and Biosimilars by Type (2022-2030)
10.1.2 Global Forecasted Revenue of Biologics and Biosimilars by Type (2022-2030)
10.2 Biologics and Biosimilars Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Biologics and Biosimilars by Application (2022-2030)
10.2.2 Global Forecasted Revenue of Biologics and Biosimilars by Application (2022-2030)
10.3 Biologics and Biosimilars Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Biologics and Biosimilars by Region (2022-2030)
10.3.2 Global Forecasted Revenue of Biologics and Biosimilars by Region (2022-2030)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
1.1 Product Overview and Scope of Biologics and Biosimilars
1.2 Biologics and Biosimilars Segment by Type
1.2.1 Global Biologics and Biosimilars Sales Growth Rate Comparison by Type (2022-2030)
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Others
1.3 Biologics and Biosimilars Segment by Application
1.3.1 Biologics and Biosimilars Sales Comparison by Application: (2022-2030)
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Others
1.4 Global Biologics and Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Biologics and Biosimilars Revenue 2016-2030
1.4.2 Global Biologics and Biosimilars Sales 2016-2030
1.4.3 Biologics and Biosimilars Market Size by Region: 2016 Versus 2022 Versus 2030
2 Biologics and Biosimilars Market Competition by Manufacturers
2.1 Global Biologics and Biosimilars Sales Market Share by Manufacturers (2016-2021)
2.2 Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Biologics and Biosimilars Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Biologics and Biosimilars Manufacturing Sites, Area Served, Product Type
2.5 Biologics and Biosimilars Market Competitive Situation and Trends
2.5.1 Biologics and Biosimilars Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Biologics and Biosimilars Players Market Share by Revenue
2.5.3 Global Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biologics and Biosimilars Retrospective Market Scenario by Region
3.1 Global Biologics and Biosimilars Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Biologics and Biosimilars Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Biologics and Biosimilars Market Facts & Figures by Country
3.3.1 North America Biologics and Biosimilars Sales by Country
3.3.2 North America Biologics and Biosimilars Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Biologics and Biosimilars Market Facts & Figures by Country
3.4.1 Europe Biologics and Biosimilars Sales by Country
3.4.2 Europe Biologics and Biosimilars Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Biologics and Biosimilars Market Facts & Figures by Region
3.5.1 Asia Pacific Biologics and Biosimilars Sales by Region
3.5.2 Asia Pacific Biologics and Biosimilars Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Biologics and Biosimilars Market Facts & Figures by Country
3.6.1 Latin America Biologics and Biosimilars Sales by Country
3.6.2 Latin America Biologics and Biosimilars Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Biologics and Biosimilars Market Facts & Figures by Country
3.7.1 Middle East and Africa Biologics and Biosimilars Sales by Country
3.7.2 Middle East and Africa Biologics and Biosimilars Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Biologics and Biosimilars Historic Market Analysis by Type
4.1 Global Biologics and Biosimilars Sales Market Share by Type (2016-2021)
4.2 Global Biologics and Biosimilars Revenue Market Share by Type (2016-2021)
4.3 Global Biologics and Biosimilars Price by Type (2016-2021)
5 Global Biologics and Biosimilars Historic Market Analysis by Application
5.1 Global Biologics and Biosimilars Sales Market Share by Application (2016-2021)
5.2 Global Biologics and Biosimilars Revenue Market Share by Application (2016-2021)
5.3 Global Biologics and Biosimilars Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Roche Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Amgen Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 AbbVie
6.3.1 AbbVie Corporation Information
6.3.2 AbbVie Description and Business Overview
6.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.3.4 AbbVie Product Portfolio
6.3.5 AbbVie Recent Developments/Updates
6.4 Sanofi-Aventis
6.4.1 Sanofi-Aventis Corporation Information
6.4.2 Sanofi-Aventis Description and Business Overview
6.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Sanofi-Aventis Product Portfolio
6.4.5 Sanofi-Aventis Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Corporation Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Johnson & Johnson Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Pfizer Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Novo Nordisk
6.6.1 Novo Nordisk Corporation Information
6.6.2 Novo Nordisk Description and Business Overview
6.6.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Novo Nordisk Product Portfolio
6.7.5 Novo Nordisk Recent Developments/Updates
6.8 Eli Lilly
6.8.1 Eli Lilly Corporation Information
6.8.2 Eli Lilly Description and Business Overview
6.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Eli Lilly Product Portfolio
6.8.5 Eli Lilly Recent Developments/Updates
6.9 Novartis
6.9.1 Novartis Corporation Information
6.9.2 Novartis Description and Business Overview
6.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Novartis Product Portfolio
6.9.5 Novartis Recent Developments/Updates
6.10 Merck
6.10.1 Merck Corporation Information
6.10.2 Merck Description and Business Overview
6.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Merck Product Portfolio
6.10.5 Merck Recent Developments/Updates
6.11 3sbio
6.11.1 3sbio Corporation Information
6.11.2 3sbio Biologics and Biosimilars Description and Business Overview
6.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.11.4 3sbio Product Portfolio
6.11.5 3sbio Recent Developments/Updates
6.12 Changchun High Tech
6.12.1 Changchun High Tech Corporation Information
6.12.2 Changchun High Tech Biologics and Biosimilars Description and Business Overview
6.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Changchun High Tech Product Portfolio
6.12.5 Changchun High Tech Recent Developments/Updates
6.13 CP Guojian
6.13.1 CP Guojian Corporation Information
6.13.2 CP Guojian Biologics and Biosimilars Description and Business Overview
6.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.13.4 CP Guojian Product Portfolio
6.13.5 CP Guojian Recent Developments/Updates
6.14 Biotech
6.14.1 Biotech Corporation Information
6.14.2 Biotech Biologics and Biosimilars Description and Business Overview
6.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Biotech Product Portfolio
6.14.5 Biotech Recent Developments/Updates
6.15 Gelgen
6.15.1 Gelgen Corporation Information
6.15.2 Gelgen Biologics and Biosimilars Description and Business Overview
6.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Gelgen Product Portfolio
6.15.5 Gelgen Recent Developments/Updates
6.16 Innovent
6.16.1 Innovent Corporation Information
6.16.2 Innovent Biologics and Biosimilars Description and Business Overview
6.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Innovent Product Portfolio
6.16.5 Innovent Recent Developments/Updates
6.17 Dong Bao
6.17.1 Dong Bao Corporation Information
6.17.2 Dong Bao Biologics and Biosimilars Description and Business Overview
6.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Dong Bao Product Portfolio
6.17.5 Dong Bao Recent Developments/Updates
6.18 Ganlee
6.18.1 Ganlee Corporation Information
6.18.2 Ganlee Biologics and Biosimilars Description and Business Overview
6.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.18.4 Ganlee Product Portfolio
6.18.5 Ganlee Recent Developments/Updates
7 Biologics and Biosimilars Manufacturing Cost Analysis
7.1 Biologics and Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Biologics and Biosimilars
7.4 Biologics and Biosimilars Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Biologics and Biosimilars Distributors List
8.3 Biologics and Biosimilars Customers
9 Biologics and Biosimilars Market Dynamics
9.1 Biologics and Biosimilars Industry Trends
9.2 Biologics and Biosimilars Growth Drivers
9.3 Biologics and Biosimilars Market Challenges
9.4 Biologics and Biosimilars Market Restraints
10 Global Market Forecast
10.1 Biologics and Biosimilars Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Biologics and Biosimilars by Type (2022-2030)
10.1.2 Global Forecasted Revenue of Biologics and Biosimilars by Type (2022-2030)
10.2 Biologics and Biosimilars Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Biologics and Biosimilars by Application (2022-2030)
10.2.2 Global Forecasted Revenue of Biologics and Biosimilars by Application (2022-2030)
10.3 Biologics and Biosimilars Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Biologics and Biosimilars by Region (2022-2030)
10.3.2 Global Forecasted Revenue of Biologics and Biosimilars by Region (2022-2030)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.
}})
Pricing
Select a license type that suits your business needs
Single User Access
US $3950
Only Three Thousand Nine Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
Multi User Cost
US $4950
Only Four Thousand Nine Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
Enterprise User Cost
US $5950
Only Five Thousand Nine Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI